Key Achievements 2022

The focus during the financial year ended 30 June 2022 has been to progress the growth and expansion strategy to diversify towards a sustainable pharmaceutical group.

Expansion of Melanocortin Drug Portfolio

  • Introduced ACTH formulation, NEURACTHEL® for acute neurological, endocrinological and degenerative disorders

Distribution of SCENESSE®

  • Continued growth in patient access in the EEA, the USA and Israel
  • Reimbursement of SCENESSE® agreed with State and Private insurers in Germany

Healthcare Solutions Progressed

  • Ongoing development of a dermatocosmetic product range
  • Digital marketing campaign commenced ahead of first product launch

Expanded Clinical Programs Advanced

  • First stroke study commenced, completed and results announced
  • Three studies commenced in DNA Repair Program
  • Design of new vitiligo study agreed; SCENESSE® to be evaluated as monotherapy

Strong Financial Performance

  • Growth reflected in record operating profit, half year to 31 December 2021 and full year to 30 June 2022
  • Sixth consecutive annual profit delivered
  • Highest cash receipts for a September, December, March, and June quarter achieved throughout the year
  • Fifth consecutive annual dividend declared
  • Cash balances rose to over A$121 million to enable self-financing of key initiatives